UNSPSC 51385701: Deracoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C17H14F3N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VX29JB5XWV, chemically known as benzenesulfonamide, 4-(3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1h-pyrazol-1-yl)- but generally known as deracoxib, which bears US NIH Compound Identifier 3058754. European Medicines Agency schedules Deracoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01594MIG.

UNSPSC 51385701 Deracoxib is a Commodity code designating a specific veterinary pharmaceutical product, yet the recent state and local activity recorded under it reflects a mismatch: the single identified opportunity involves procurement of naloxone and safe drug deactivation systems for community health use, not deracoxib veterinary supply. State and local governments sourcing under this code appear limited; the available record shows no issuing bodies routinely procuring deracoxib itself, and the naloxone procurement does not align with the code's nominal scope. The work nominally covered by the code — veterinary anti-inflammatory medication — does not surface in recent state and local solicitations.

Seminole County, Florida posted the only recent opportunity in the dataset, an IFB (IFB60459723LAS) released June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The bid response deadline was July 26, 2023 (note: the posted date and due date show inconsistent year notation in the source). The county required electronic submission through its e-Procurement Portal, inclusion of all shipping and delivery costs in pricing, E-Verify compliance, and drug-free workplace certification. The contract carried an initial two-year term with one-year renewal option and potential FEMA funding with corresponding federal compliance obligations. This code shows little relevant recent activity and warrants investigation into whether state and local procurement offices are correctly tagging veterinary pharmaceutical buys or whether deracoxib demand from state and local animal health programs remains below visibility in current solicitation records.